Literature DB >> 16166613

Walking versus cycling: sensitivity to bronchodilation in chronic obstructive pulmonary disease.

Véronique Pepin1, Didier Saey, Francçois Whittom, Pierre LeBlanc, Francçois Maltais.   

Abstract

RATIONALE: There is no consensus regarding which exercise test to use to evaluate the functional impact of bronchodilators in patients with chronic obstructive pulmonary disease. OBJECTIVE AND METHODS: Bronchodilator-induced changes in endurance time were evaluated during cycling and walking in 17 patients with chronic obstructive pulmonary disease who completed two cycle endurance tests and two endurance shuttle walks at 80% of peak capacity. Each endurance test was preceded by the nebulization of a placebo or 500 microg of ipratropium bromide using a randomized, double-blind, crossover design. Quadriceps twitch force was measured with magnetic stimulation of the femoral nerve before and after each endurance test.
RESULTS: Cycling endurance time did not improve significantly after bronchodilation despite a significant increase in FEV1 (delta endurance time ipratropium bromide - placebo: 51 +/- 255 s, p = 0.42). A similar change in FEV1 was associated with a significant improvement in walking endurance time (delta endurance time ipratropium bromide - placebo: 164 +/- 177 s, p < 0.01). A 22 +/- 17% fall in quadriceps twitch force was observed after cycling, whereas no significant change was seen after walking.
CONCLUSION: The endurance shuttle walk is a sensitive test to detect changes in exercise tolerance after bronchodilation. Differences in the occurrence of quadriceps muscle fatigue may explain, in part, the different responsiveness to change between cycling and walking.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16166613     DOI: 10.1164/rccm.200507-1037OC

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  22 in total

1.  Six-minute walking versus shuttle walking: responsiveness to bronchodilation in chronic obstructive pulmonary disease.

Authors:  Véronique Pepin; Julie Brodeur; Yves Lacasse; Julie Milot; Pierre Leblanc; François Whittom; François Maltais
Journal:  Thorax       Date:  2006-11-10       Impact factor: 9.139

2.  Assessing the exercise response to a bronchodilator in COPD: time to get off your bike?

Authors:  M D L Morgan; S J Singh
Journal:  Thorax       Date:  2007-04       Impact factor: 9.139

Review 3.  COPD: what is the unmet need?

Authors:  P M A Calverley
Journal:  Br J Pharmacol       Date:  2008-09-15       Impact factor: 8.739

Review 4.  An official American Thoracic Society/European Respiratory Society statement: update on limb muscle dysfunction in chronic obstructive pulmonary disease.

Authors:  François Maltais; Marc Decramer; Richard Casaburi; Esther Barreiro; Yan Burelle; Richard Debigaré; P N Richard Dekhuijzen; Frits Franssen; Ghislaine Gayan-Ramirez; Joaquim Gea; Harry R Gosker; Rik Gosselink; Maurice Hayot; Sabah N A Hussain; Wim Janssens; Micheal I Polkey; Josep Roca; Didier Saey; Annemie M W J Schols; Martijn A Spruit; Michael Steiner; Tanja Taivassalo; Thierry Troosters; Ioannis Vogiatzis; Peter D Wagner
Journal:  Am J Respir Crit Care Med       Date:  2014-05-01       Impact factor: 21.405

Review 5.  Impact of bronchodilator therapy on exercise tolerance in COPD.

Authors:  B Aguilaniu
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2010-04-07

6.  Development and implementation of treadmill exercise testing protocols in COPD.

Authors:  Christopher B Cooper; Marlon Abrazado; Daniel Legg; Steven Kesten
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2010-10-12

7.  Nordic walking improves daily physical activities in COPD: a randomised controlled trial.

Authors:  Marie-Kathrin Breyer; Robab Breyer-Kohansal; Georg-Christian Funk; Nicole Dornhofer; Martijn A Spruit; Emiel F M Wouters; Otto C Burghuber; Sylvia Hartl
Journal:  Respir Res       Date:  2010-08-22

8.  The 6-Minute-Walk Distance Test as a Chronic Obstructive Pulmonary Disease Stratification Tool. Insights from the COPD Biomarker Qualification Consortium.

Authors:  Bartolome Celli; Kay Tetzlaff; Gerard Criner; Michael I Polkey; Frank Sciurba; Richard Casaburi; Ruth Tal-Singer; Ariane Kawata; Debora Merrill; Stephen Rennard
Journal:  Am J Respir Crit Care Med       Date:  2016-12-15       Impact factor: 21.405

Review 9.  New modalities of pulmonary rehabilitation in patients with chronic obstructive pulmonary disease.

Authors:  Martijn A Spruit; Emiel F M Wouters
Journal:  Sports Med       Date:  2007       Impact factor: 11.136

10.  Once-daily NVA237 improves exercise tolerance from the first dose in patients with COPD: the GLOW3 trial.

Authors:  Kai M Beeh; Dave Singh; Lilla Di Scala; Anton Drollmann
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2012-07-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.